BC Extra | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
BC Innovations | Jul 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies identified a chimeric IL-2 -Fc fusion protein that could help treat cancer. The fusion protein consisted of a human IL-2 variant containing three point mutations, linked to the Fc domain of...
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

Recombinant IL-2 was one of the first immunotherapies marketed for cancer but is not widely used due to severe off-target toxicities. Cue Biopharma Inc. is developing preclinical programs that deliver IL-2 only to T cells...
BC Innovations | Dec 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest IL-2 complexed with an anti-IL-2 antibody could help treat metastatic melanoma. In cell-based assays, the antibody blocked CD25 binding to IL-2 and prevented expansion of CD25-positive Tregs,...
BC Innovations | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
BC Week In Review | Feb 8, 2016
Clinical News

Darleukin: Phase III started

Philogen began an open-label, international Phase III trial to evaluate 13 million international units (MIU) of intralesional L19-IL2 in combination with 400 ug intralesional L19-TNF given weekly for 4 weeks in about 214 patients. Philogen’s...
BC Week In Review | Feb 8, 2016
Clinical News

Fibromun: Phase III started

Philogen began an open-label, international Phase III trial to evaluate 13 million international units (MIU) of intralesional L19-IL2 in combination with 400 ug intralesional L19-TNF given weekly for 4 weeks in about 214 patients. Philogen’s...
BC Week In Review | Jun 13, 2011
Clinical News

Darleukin: Phase II data

A Phase II trial in 29 evaluable patients showed that IV darleukin led to 8 objective responses, including 1 ongoing complete response 21 months after the start of treatment. Median OS was 14.4 months with...
BC Week In Review | Feb 21, 2011
Company News

Philogen, Bayer deal

Philogen's most advanced compound, Darleukin ( L19-IL2 ), a fusion protein consisting of the human vascular targeting antibody L19 and IL-2, has completed Phase II testing to treat renal cell carcinoma. Philogen S.p.A. , Siena, Italy  ...
Items per page:
1 - 10 of 15